GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Medicus Sciences Acquisition Corp (NAS:MSAC) » Definitions » Sloan Ratio %

MSAC (Medicus Sciences Acquisition) Sloan Ratio % : 0.00% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Medicus Sciences Acquisition Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Medicus Sciences Acquisition's Sloan Ratio for the quarter that ended in Sep. 2022 was 0.00%.

As of Sep. 2022, Medicus Sciences Acquisition has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Medicus Sciences Acquisition Sloan Ratio % Historical Data

The historical data trend for Medicus Sciences Acquisition's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Sciences Acquisition Sloan Ratio % Chart

Medicus Sciences Acquisition Annual Data
Trend Dec20 Dec21
Sloan Ratio %
- 101.15

Medicus Sciences Acquisition Quarterly Data
Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Sloan Ratio % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Medicus Sciences Acquisition's Sloan Ratio %

For the Shell Companies subindustry, Medicus Sciences Acquisition's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicus Sciences Acquisition's Sloan Ratio % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Medicus Sciences Acquisition's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Medicus Sciences Acquisition's Sloan Ratio % falls into.



Medicus Sciences Acquisition Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Medicus Sciences Acquisition's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2021 )-Cash Flow from Operations (A: Dec. 2021 )
-Cash Flow from Investing (A: Dec. 2021 ))/Total Assets (A: Dec. 2021 )
=(1.898--0.799
--92)/93.624
=101.15%

Medicus Sciences Acquisition's Sloan Ratio for the quarter that ended in Sep. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2022 )
=(3.941--0.609
-0)/93.432
=4.87%

Medicus Sciences Acquisition's Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was -0.265 (Dec. 2021 ) + 2.253 (Mar. 2022 ) + 1.57 (Jun. 2022 ) + 0.383 (Sep. 2022 ) = $3.94 Mil.
Medicus Sciences Acquisition's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2022 was -0.151 (Dec. 2021 ) + -0.137 (Mar. 2022 ) + -0.232 (Jun. 2022 ) + -0.089 (Sep. 2022 ) = $-0.61 Mil.
Medicus Sciences Acquisition's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2022 was 0 (Dec. 2021 ) + 0 (Mar. 2022 ) + 0 (Jun. 2022 ) + 0 (Sep. 2022 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicus Sciences Acquisition  (NAS:MSAC) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2022, Medicus Sciences Acquisition has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Medicus Sciences Acquisition Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Medicus Sciences Acquisition's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicus Sciences Acquisition Business Description

Traded in Other Exchanges
N/A
Address
152 West 57th Street, Floor 20, New York, NY, USA, 10019
Medicus Sciences Acquisition Corp is a blank check company.
Executives
Eric Cheng officer: Chief Business Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Kenneth Berkovitz director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Christopher Kaster director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Ross Levine director 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Judah Drillick officer: Chief Financial Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Jacob Gottlieb director, 10 percent owner, officer: Executive Chairman 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Medicus Sciences Holdings Llc 10 percent owner 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019
Michael Castor director, 10 percent owner, officer: Chief Executive Officer 152 WEST 57TH STREET, FLOOR 20, NEW YORK NY 10019